New combo therapy aims to boost immune attack on tough breast cancer

NCT ID NCT06735131

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing different ways to combine radiotherapy with the immunotherapy drug toripalimab and chemotherapy for people with advanced triple-negative breast cancer (TNBC). The goal is to find the best schedule that helps control the cancer longer. About 60 participants will receive one of several radiotherapy patterns alongside standard treatment, and researchers will track how many are still progression-free after 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
toripalimab (immunotherapy) plus radiotherapy and chemotherapy
What this could lead to
If successful, this could establish a more effective combination treatment for advanced triple-negative breast cancer, potentially improving how long patients live without their cancer worsening.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to all patients. The added radiotherapy also carries risks like fatigue, skin reactions, or inflammation of nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.